RE: Year of the Ox27 Feb 2021 17:04
Hopefully any future upfront fee is advertised in the RNS with our new CEO looking to win over shareholders.
There were too many games being played with regards to Ebers, Vistagen and Oxillo, when they chose not to disclose any figures. We need transparency after losing so much sentiment over the last year.